Tags

Type your tag names separated by a space and hit enter

A miniaturized flow-through cell to evaluate skin permeation of endoxifen.
Int J Pharm 2013; 441(1-2):433-40IJ

Abstract

Endoxifen, an anti-estrogenic agent, has been recently implicated in the use of breast cancer. Its physicochemical properties make it a good candidate for transdermal delivery. However, as an investigative drug, its limited supply makes it difficult to conduct extensive pre-formulation studies. To address this issue, a miniaturized flow-through diffusion cell has been fabricated that utilized minimal amounts of the drug for in vitro skin permeation studies. The novel flow-through cells have been validated against horizontal diffusion cells and shown to cause no noticeable damage to the applied skin, as observed by histological sectioning. The cells were also demonstrated to be useful in search of suitable enhancers for endoxifen. Endoxifen permeation using permeation enhancers was tested by using this new device and limonene was found to achieve highest flux, attaining the requirement for clinical applications. The fabricated cells can thus be useful in carrying out pre-formulation studies for expensive, new drug entities, both in industrial as well as academic research.

Authors+Show Affiliations

Department of Pharmacy, National University of Singapore, 18 Science Drive 4, 117543, Singapore.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Validation Studies

Language

eng

PubMed ID

23174412

Citation

Mah, Choon Siong, et al. "A Miniaturized Flow-through Cell to Evaluate Skin Permeation of Endoxifen." International Journal of Pharmaceutics, vol. 441, no. 1-2, 2013, pp. 433-40.
Mah CS, Kochhar JS, Ong PS, et al. A miniaturized flow-through cell to evaluate skin permeation of endoxifen. Int J Pharm. 2013;441(1-2):433-40.
Mah, C. S., Kochhar, J. S., Ong, P. S., & Kang, L. (2013). A miniaturized flow-through cell to evaluate skin permeation of endoxifen. International Journal of Pharmaceutics, 441(1-2), pp. 433-40. doi:10.1016/j.ijpharm.2012.11.011.
Mah CS, et al. A Miniaturized Flow-through Cell to Evaluate Skin Permeation of Endoxifen. Int J Pharm. 2013 Jan 30;441(1-2):433-40. PubMed PMID: 23174412.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A miniaturized flow-through cell to evaluate skin permeation of endoxifen. AU - Mah,Choon Siong, AU - Kochhar,Jaspreet Singh, AU - Ong,Pei Shi, AU - Kang,Lifeng, Y1 - 2012/11/19/ PY - 2012/05/23/received PY - 2012/10/11/revised PY - 2012/11/09/accepted PY - 2012/11/24/entrez PY - 2012/11/24/pubmed PY - 2013/8/3/medline SP - 433 EP - 40 JF - International journal of pharmaceutics JO - Int J Pharm VL - 441 IS - 1-2 N2 - Endoxifen, an anti-estrogenic agent, has been recently implicated in the use of breast cancer. Its physicochemical properties make it a good candidate for transdermal delivery. However, as an investigative drug, its limited supply makes it difficult to conduct extensive pre-formulation studies. To address this issue, a miniaturized flow-through diffusion cell has been fabricated that utilized minimal amounts of the drug for in vitro skin permeation studies. The novel flow-through cells have been validated against horizontal diffusion cells and shown to cause no noticeable damage to the applied skin, as observed by histological sectioning. The cells were also demonstrated to be useful in search of suitable enhancers for endoxifen. Endoxifen permeation using permeation enhancers was tested by using this new device and limonene was found to achieve highest flux, attaining the requirement for clinical applications. The fabricated cells can thus be useful in carrying out pre-formulation studies for expensive, new drug entities, both in industrial as well as academic research. SN - 1873-3476 UR - https://www.unboundmedicine.com/medline/citation/23174412/A_miniaturized_flow_through_cell_to_evaluate_skin_permeation_of_endoxifen_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0378-5173(12)01018-6 DB - PRIME DP - Unbound Medicine ER -